Company intelligence / Profile preview

EHT Technologies

Hamburg, Hamburg, Germany

Ownership: Private
Development stage: Other

Overview

EHT Technologies developed a proprietary engineered heart tissue platform using human induced pluripotent stem cell–derived cardiomyocytes to create 3D cardiac constructs for disease modeling, cardiac safety and efficacy testing, and gene therapy applications; the platform has been validated for efficient transduction with adeno-associated virus vectors including AAV9, supporting its use in preclinical gene therapy research for conditions such as hypertrophic cardiomyopathy.[1]

Therapeutic areas: Cardiovascular
Modalities: Cell therapy3D tissue modelDevice
Industry: Non-Drug Biotech

Partnerships

DiNAQOR (acquirer and integrator of the EHT platform for gene therapy discovery and preclinical development)[1][3]

Beyond the preview

Go deeper on EHT Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EHT Technologies.

Explore the full profile